A16z-Backed Biotech Braveheart Seeks $318.8 Million in US IPO

Braveheart Bio Inc., a clinical-stage biopharmaceutical company, filed to raise up to $318.8 million in an initial public offering. The company is backed by venture capital firm Andreessen Horowitz. The IPO filing adds to the number of biotech companies going public in 2026.

Next story